JP2010518168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518168A5 JP2010518168A5 JP2009549685A JP2009549685A JP2010518168A5 JP 2010518168 A5 JP2010518168 A5 JP 2010518168A5 JP 2009549685 A JP2009549685 A JP 2009549685A JP 2009549685 A JP2009549685 A JP 2009549685A JP 2010518168 A5 JP2010518168 A5 JP 2010518168A5
- Authority
- JP
- Japan
- Prior art keywords
- tramadol
- inhibitor
- pharmaceutically acceptable
- pde5
- acceptable form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 36
- 229960004380 tramadol Drugs 0.000 claims 29
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 29
- 239000000463 material Substances 0.000 claims 25
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 24
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 22
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 18
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 17
- 239000003638 chemical reducing agent Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 9
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 8
- 229960002639 sildenafil citrate Drugs 0.000 claims 8
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 8
- 229960000835 tadalafil Drugs 0.000 claims 8
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 5
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 claims 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 4
- 229960003086 naltrexone Drugs 0.000 claims 4
- 239000003401 opiate antagonist Substances 0.000 claims 4
- 229960003310 sildenafil Drugs 0.000 claims 4
- 229960002381 vardenafil Drugs 0.000 claims 4
- 229960001540 vardenafil hydrochloride Drugs 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 206010036596 premature ejaculation Diseases 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 230000036299 sexual function Effects 0.000 claims 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims 1
- 206010002652 Anorgasmia Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88938007P | 2007-02-12 | 2007-02-12 | |
| US60/889,380 | 2007-02-12 | ||
| PCT/US2008/053722 WO2008100933A2 (en) | 2007-02-12 | 2008-02-12 | Reducing side effects of tramadol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518168A JP2010518168A (ja) | 2010-05-27 |
| JP2010518168A5 true JP2010518168A5 (enExample) | 2012-01-26 |
| JP5550101B2 JP5550101B2 (ja) | 2014-07-16 |
Family
ID=39690762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549685A Expired - Fee Related JP5550101B2 (ja) | 2007-02-12 | 2008-02-12 | トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20080261991A1 (enExample) |
| EP (2) | EP2486921A1 (enExample) |
| JP (1) | JP5550101B2 (enExample) |
| KR (2) | KR20130122023A (enExample) |
| CN (1) | CN101674728A (enExample) |
| AU (1) | AU2008216363B2 (enExample) |
| BR (1) | BRPI0807281A2 (enExample) |
| CA (1) | CA2677691C (enExample) |
| DK (1) | DK2114147T3 (enExample) |
| ES (1) | ES2384127T3 (enExample) |
| MX (1) | MX2009008511A (enExample) |
| NZ (1) | NZ579170A (enExample) |
| PL (1) | PL2114147T3 (enExample) |
| SG (1) | SG178775A1 (enExample) |
| WO (1) | WO2008100933A2 (enExample) |
| ZA (1) | ZA200906187B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130122023A (ko) * | 2007-02-12 | 2013-11-06 | 디엠아이 바이오사이언시스 인코포레이티드 | 트라마돌의 부작용을 감소시키는 방법 |
| SG174079A1 (en) * | 2007-02-12 | 2011-09-29 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction |
| US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| WO2012142273A1 (en) * | 2011-04-12 | 2012-10-18 | Revogenex Inc. | Intravenous administration of tramadol |
| WO2015134695A1 (en) * | 2014-03-07 | 2015-09-11 | Vyrix Pharmaceuticals, Inc. | Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject |
| US20160228485A1 (en) * | 2015-02-11 | 2016-08-11 | Latasha M. Watts | Skin medicating system |
| US9980900B2 (en) | 2015-12-22 | 2018-05-29 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
| US9693949B1 (en) | 2015-12-22 | 2017-07-04 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
| US10022321B2 (en) | 2016-06-30 | 2018-07-17 | Revogenex Ireland Ltd. | Intravenous administration of tramadol |
| WO2020006606A1 (en) * | 2018-07-05 | 2020-01-09 | Helium 3 Resources Pty Ltd | A pharmaceutical composition and method of use of same |
| WO2022026591A1 (en) * | 2020-07-29 | 2022-02-03 | Kydes Pharmaceuticals, Llc | Pharmaceutical formulations comprising tadalafil |
| US11504332B2 (en) * | 2021-03-23 | 2022-11-22 | Vk Research Associates Inc. | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3830934A (en) | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
| US3652589A (en) | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| CA2352552C (en) | 1990-04-25 | 2008-12-02 | Virgil A. Place | Treatment of erectile dysfunction |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5151448A (en) * | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
| ATE169498T1 (de) | 1991-09-06 | 1998-08-15 | Mcneilab Inc | Zusammensetzung, die eine tramadol-verbindung und acetaminophen enthält, und ihre verwendung |
| US5223541A (en) * | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DE19601744C2 (de) | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
| DE19601745C1 (de) | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
| IL119121A (en) | 1996-08-22 | 2000-11-21 | Chemagis Ltd | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| ES2227814T3 (es) | 1997-03-11 | 2005-04-01 | Arakis Ltd. | Formas de dosificacion que comprenden porciones separadas de enantiomeros r y s. |
| AU6747698A (en) * | 1997-04-11 | 1998-11-11 | Nippon Shinyaku Co. Ltd. | Remedies for frequent urination and urinary incontinence |
| US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6037360A (en) | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
| PT1049695E (pt) | 1997-11-12 | 2002-07-31 | Bayer Ag | Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase |
| US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| UA55507C2 (uk) * | 1997-12-22 | 2003-04-15 | Еро-Селтік, С.А. | Лікарська форма для перорального введення та спосіб запобігання зловживанню пероральною опіоїдною композицією |
| WO1999032120A1 (en) * | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
| US6339826B2 (en) * | 1998-05-05 | 2002-01-15 | International Business Machines Corp. | Client-server system for maintaining a user desktop consistent with server application user access permissions |
| GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| PL347542A1 (en) | 1998-12-02 | 2002-04-08 | Darwin Discovery Ltd | Therapeutic product and its use |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| US20030055070A1 (en) * | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
| US6821975B1 (en) | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| EP1313460A2 (en) | 1999-11-09 | 2003-05-28 | Darwin Discovery Limited | Therapeutic use and formulation of (-)-tramadol |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| CA2758923A1 (en) * | 2001-03-16 | 2002-09-26 | Dmi Biosciences, Inc. | Use of tramadol to delay ejaculation |
| WO2002092059A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
| JP4504013B2 (ja) * | 2001-08-06 | 2010-07-14 | ユーロ−セルティーク エス．エイ． | 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤 |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| MXPA04004370A (es) | 2001-11-09 | 2004-08-11 | Schering Corp | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. |
| AU2003217669A1 (en) * | 2002-02-25 | 2003-09-09 | Smithkline Beecham Corporation | A method of recuding anti-neoplastic agent induced side effects |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
| US20060149480A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Method of making combination medicament and medicament made thereby |
| JP4475098B2 (ja) * | 2004-11-02 | 2010-06-09 | ソニー株式会社 | 記憶素子及びその駆動方法 |
| KR20070107099A (ko) * | 2005-03-01 | 2007-11-06 | 화이자 리미티드 | 신경병증성 통증의 치료를 위한 ｐｄｅ7 억제제의 용도 |
| JP5528705B2 (ja) * | 2005-12-13 | 2014-06-25 | トリニティ ラボラトリーズ インコーポレイテッド | ヒトにおける早漏を治療するための方法 |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| KR20130122023A (ko) * | 2007-02-12 | 2013-11-06 | 디엠아이 바이오사이언시스 인코포레이티드 | 트라마돌의 부작용을 감소시키는 방법 |
| SG174079A1 (en) * | 2007-02-12 | 2011-09-29 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction |
| WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
-
2008
- 2008-02-12 KR KR1020137027225A patent/KR20130122023A/ko not_active Withdrawn
- 2008-02-12 AU AU2008216363A patent/AU2008216363B2/en not_active Ceased
- 2008-02-12 SG SG2012009536A patent/SG178775A1/en unknown
- 2008-02-12 WO PCT/US2008/053722 patent/WO2008100933A2/en not_active Ceased
- 2008-02-12 EP EP12167725A patent/EP2486921A1/en not_active Withdrawn
- 2008-02-12 CN CN200880011692A patent/CN101674728A/zh active Pending
- 2008-02-12 KR KR1020097018879A patent/KR101497509B1/ko active Active
- 2008-02-12 BR BRPI0807281-7A2A patent/BRPI0807281A2/pt not_active IP Right Cessation
- 2008-02-12 CA CA2677691A patent/CA2677691C/en not_active Expired - Fee Related
- 2008-02-12 DK DK08729655.4T patent/DK2114147T3/da active
- 2008-02-12 JP JP2009549685A patent/JP5550101B2/ja not_active Expired - Fee Related
- 2008-02-12 ES ES08729655T patent/ES2384127T3/es active Active
- 2008-02-12 NZ NZ579170A patent/NZ579170A/en not_active IP Right Cessation
- 2008-02-12 US US12/029,973 patent/US20080261991A1/en not_active Abandoned
- 2008-02-12 MX MX2009008511A patent/MX2009008511A/es active IP Right Grant
- 2008-02-12 EP EP08729655.4A patent/EP2114147B9/en active Active
- 2008-02-12 PL PL08729655T patent/PL2114147T3/pl unknown
-
2009
- 2009-09-07 ZA ZA2009/06187A patent/ZA200906187B/en unknown
-
2011
- 2011-09-28 US US13/247,450 patent/US20120018333A1/en not_active Abandoned
-
2013
- 2013-08-19 US US13/970,198 patent/US20130338166A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518168A5 (enExample) | ||
| CA2677691A1 (en) | Reducing side effects of tramadol | |
| WO2012005500A3 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| JP2005512995A5 (enExample) | ||
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2007533686A5 (enExample) | ||
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| UA93543C2 (ru) | Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон | |
| JP2016539156A5 (enExample) | ||
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2010536849A5 (enExample) | ||
| JP2013542246A5 (enExample) | ||
| JP2010535805A5 (enExample) | ||
| WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| JP2010518167A5 (ja) | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット | |
| JP2009518415A5 (enExample) | ||
| MX347237B (es) | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. | |
| WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
| CA2677690A1 (en) | Treatment of comorbid premature ejaculation and erectile dysfunction | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| JP2015521647A5 (enExample) | ||
| JP2012504112A5 (enExample) |